Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BNOS 2022 | Novel perspectives in glioblastoma immunotherapy

Hemanth Vupputuri, MBBS, The Walton Centre NHS Foundation Trust, Liverpool, UK, comments on the need for more immunotherapies in the field of glioblastoma. Whilst patients with other cancers such as breast cancer have benefited from immunotherapy, patients with primary brain tumors including glioblastoma still have average survival rates of under a year. The development of monoclonal antibodies will hence optimize outcomes for patients with glioblastoma. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.